Zynex Inc. (OTCMKTS:ZYXI) CFO Daniel J. Moorhead bought 2,733 shares of Zynex stock in a transaction on Thursday, July 30th. The shares were purchased at an average price of $18.11 per share, for a total transaction of $49,494.63. Following the acquisition, the chief financial officer now directly owns 19,001 shares in the company, valued at approximately $344,108.11. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ZYXI stock opened at $19.12 on Friday. The stock has a market capitalization of $663.58 million, a PE ratio of 86.91 and a beta of 1.05. Zynex Inc. has a 12-month low of $7.51 and a 12-month high of $29.73. The stock’s 50 day simple moving average is $23.36 and its 200 day simple moving average is $16.05.

Zynex (OTCMKTS:ZYXI) last released its quarterly earnings data on Tuesday, July 28th. The company reported $0.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.09. The business had revenue of $19.26 million for the quarter, compared to analysts’ expectations of $19.12 million. Zynex had a return on equity of 152.81% and a net margin of 33.33%. As a group, analysts predict that Zynex Inc. will post 0.28 EPS for the current year.

A number of research firms have weighed in on ZYXI. Northland Securities reiterated a “hold” rating and set a $22.50 target price on shares of Zynex in a report on Wednesday. B. Riley raised Zynex from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Wednesday. Piper Sandler initiated coverage on Zynex in a research report on Monday, July 20th. They issued an “overweight” rating and a $30.00 price target on the stock. Finally, HC Wainwright dropped their price target on Zynex from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Zynex currently has a consensus rating of “Buy” and an average price target of $23.50.

Institutional investors have recently modified their holdings of the company. Citigroup Inc. grew its position in shares of Zynex by 310.6% during the fourth quarter. Citigroup Inc. now owns 3,170 shares of the company’s stock valued at $25,000 after purchasing an additional 2,398 shares in the last quarter. Winslow Evans & Crocker Inc. purchased a new position in shares of Zynex during the second quarter valued at about $107,000. Strs Ohio grew its position in shares of Zynex by 84.6% during the second quarter. Strs Ohio now owns 4,800 shares of the company’s stock valued at $119,000 after purchasing an additional 2,200 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Zynex by 121.9% during the first quarter. BNP Paribas Arbitrage SA now owns 4,866 shares of the company’s stock valued at $54,000 after purchasing an additional 2,673 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund purchased a new position in shares of Zynex during the second quarter valued at about $152,000. Hedge funds and other institutional investors own 0.05% of the company’s stock.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Featured Story: High-Yield Dividend Stocks

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.